These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17536796)

  • 41. Relationship between acid secretion and blood flow in the canine stomach: role of oxygen consumption.
    Perry MA; Haedicke GJ; Bulkley GB; Kvietys PR; Granger DN
    Gastroenterology; 1983 Sep; 85(3):529-34. PubMed ID: 6873601
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Potent and subtype-selective CCK-B/gastrin receptor antagonists: 2,4-dioxo-1,5-benzodiazepines with a plane of symmetry.
    Hagishita S; Seno K; Kamata S; Haga N; Ishihara Y; Ishikawa M; Shimamura M
    Bioorg Med Chem; 1997 Jul; 5(7):1433-46. PubMed ID: 9377103
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combinatorial solid phase synthesis of multiply substituted 1,4-benzodiazepines and affinity studies on the CCK2 receptor (part 1).
    Lattmann E; Billington DC; Poyner DR; Arayarat P; Howitt SB; Lawrence S; Offel M
    Drug Des Discov; 2002; 18(1):9-21. PubMed ID: 12375632
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 3D QSAR studies of 1,3,4-benzotriazepine derivatives as CCK2 receptor antagonists.
    Kaur K; Talele TT
    J Mol Graph Model; 2008 Nov; 27(4):409-20. PubMed ID: 18774323
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacological profile of novel acid pump antagonist 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methyl cyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526).
    Ito K; Kinoshita K; Tomizawa A; Inaba F; Morikawa-Inomata Y; Makino M; Tabata K; Shibakawa N
    J Pharmacol Exp Ther; 2007 Oct; 323(1):308-17. PubMed ID: 17630360
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synthesis of phenoxyacetic acid derivatives as highly potent antagonists of gastrin/cholecystokinin-B receptors. III.
    Takeda Y; Kawagoe K; Yokomizo A; Yokomizo Y; Hosokami T; Shimoto Y; Tabuchi Y; Ogihara Y; Honda Y; Kawarabayashi K; Iseri M; Yokohama S
    Chem Pharm Bull (Tokyo); 1999 Jun; 47(6):755-71. PubMed ID: 10399834
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synthesis and structure-activity relationships of dual histamine H2 and gastrin receptor antagonists with noncyclic gastrin receptor antagonistic moieties.
    Kawanishi Y; Ishihara S; Kiyama R; Hagishita S; Tsushima T; Ishikawa M; Ishihara Y
    Bioorg Med Chem; 1997 Jul; 5(7):1425-31. PubMed ID: 9377102
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synthesis and evaluation of N-(3-oxo-2,3-dihydro-1H-pyrazol-4-yl)-1H-indole-carboxamides as cholecystokinin antagonists.
    Lattmann E; Singh H; Boonprakob Y; Lattmann P; Sattayasai J
    J Pharm Pharmacol; 2006 Mar; 58(3):393-401. PubMed ID: 16536908
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cholecystokinin antagonists: pharmacological and therapeutic potential.
    Herranz R
    Med Res Rev; 2003 Sep; 23(5):559-605. PubMed ID: 12789687
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists II: tuning of receptor selectivity and in vivo efficacy.
    Pippel M; Boyce K; Venkatesan H; Phuong VK; Yan W; Barrett TD; Lagaud G; Li L; Morton MF; Prendergast C; Wu X; Shankley NP; Rabinowitz MH
    Bioorg Med Chem Lett; 2009 Nov; 19(22):6376-8. PubMed ID: 19815410
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacological analysis of CCK2 receptors up-regulated using engineered transcription factors.
    Morton MF; Liu PQ; Reik A; de la Rosa R; Mendel M; Li XY; Case C; Pabo C; Moreno V; Pyati J; Shankley NP
    Regul Pept; 2005 Jul; 129(1-3):227-32. PubMed ID: 15927720
    [TBL] [Abstract][Full Text] [Related]  

  • 52. APD791, 3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biology.
    Adams JW; Ramirez J; Shi Y; Thomsen W; Frazer J; Morgan M; Edwards JE; Chen W; Teegarden BR; Xiong Y; Al-Shamma H; Behan DP; Connolly DT
    J Pharmacol Exp Ther; 2009 Oct; 331(1):96-103. PubMed ID: 19628629
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation.
    Parlow JJ; Burney MW; Case BL; Girard TJ; Hall KA; Hiebsch RR; Huff RM; Lachance RM; Mischke DA; Rapp SR; Woerndle RS; Ennis MD
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4657-63. PubMed ID: 19604694
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Galanin inhibits gastric acid secretion through a somatostatin-independent mechanism in mice.
    Piqueras L; Taché Y; Martinez V
    Peptides; 2004 Aug; 25(8):1287-95. PubMed ID: 15350696
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pre-clinical evaluation of a new orally-active CCK-2R antagonist, Z-360, in gastrointestinal cancer models.
    Grabowska AM; Morris TM; McKenzie AJ; Kumari R; Hamano H; Emori Y; Yoshinaga K; Watson SA
    Regul Pept; 2008 Feb; 146(1-3):46-57. PubMed ID: 17961733
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Carboxy-substituted cinnamides: a novel series of potent, orally active LTB4 receptor antagonists.
    Greenspan PD; Fujimoto RA; Marshall PJ; Raychaudhuri A; Lipson KE; Zhou H; Doti RA; Coppa DE; Zhu L; Pelletier R; Uziel-Fusi S; Jackson RH; Chin MH; Kotyuk BL; Fitt JJ
    J Med Chem; 1999 Jan; 42(1):164-72. PubMed ID: 9888841
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The ortho-nitrophenyl-sulfenyl derivative of pentagastrin: an antagonist of gastrin receptors? A promising line of research].
    Kaess H
    Gastroenterol Clin Biol; 1980 Nov; 4(11):751-3. PubMed ID: 6257579
    [No Abstract]   [Full Text] [Related]  

  • 58. [3H]A-778317 [1-((R)-5-tert-butyl-indan-1-yl)-3-isoquinolin-5-yl-urea]: a novel, stereoselective, high-affinity antagonist is a useful radioligand for the human transient receptor potential vanilloid-1 (TRPV1) receptor.
    Bianchi BR; El Kouhen R; Neelands TR; Lee CH; Gomtsyan A; Raja SN; Vaidyanathan SN; Surber B; McDonald HA; Surowy CS; Faltynek CR; Moreland RB; Jarvis MF; Puttfarcken PS
    J Pharmacol Exp Ther; 2007 Oct; 323(1):285-93. PubMed ID: 17660385
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Development of XPA067.06, a potent high affinity human anti-gastrin monoclonal antibody.
    Hsu SJ; Patel A; Larsen PD; Bohmann DJ; Bauer RJ; Ma JK; Masat L; Roell M; Babuka SJ; Hansen RK; White M; Haak-Frendscho M
    Biochem Pharmacol; 2008 Aug; 76(3):340-52. PubMed ID: 18589401
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PD-136,450: a CCK2 (gastrin) receptor antagonist with antisecretory, anxiolytic and antiulcer activity.
    Bastaki SM; Hasan MY; Chandranath SI; Schmassmann A; Garner A
    Mol Cell Biochem; 2003 Oct; 252(1-2):83-90. PubMed ID: 14577579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.